Comparative Pharmacology
Head-to-head clinical analysis: CUBICIN RF versus FOSFOMYCIN TROMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUBICIN RF versus FOSFOMYCIN TROMETHAMINE.
CUBICIN RF vs FOSFOMYCIN TROMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
3 g orally once as a single dose for uncomplicated urinary tract infection.
None Documented
None Documented
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%).
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Category C
Category A/B
Antibiotic
Antibiotic